We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
189 result(s) found, displaying 41 to 50
-
Australian public assessment report (AusPar)Mounjaro (tirzepatide) was approved, as an adjunct to a reduced-calorie diet and increased physical activity, for chronic weight management.
-
Prescription medicine registrationActive ingredients: tirzepatide.
-
-
Prescription medicine decision summaryEbglyss (lebrikizumab) is for the treatment of moderate to severe atopic dermatitis (atopic eczema) in patients older than the age of twelve.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 100 mg/mL solution for injection autoinjector (pre-filled pen).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion.
-
Prescription medicine registrationActive ingredients: lebrikizumab.
-
Australian public assessment report (AusPar)Omvoh (mirikizumab) has been approved for the treatment of moderately to severely active ulcerative colitis in adult patients
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 7.5 mg/0.5 mL solution for injection vial.